# US 11,110,152 B2 · Compositions and methods for treating and preventing lung disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,152 B2
- Document ID: US11110152B2
- Status: Granted
- Kind: B2
- Application number: 16/093,063
- Filed: 2017-04-11
- Published: 2019-04-25
- Granted: 2021-09-07
- Earliest claimed: 2016-04-11
- Assignees: Arizona Board of Regents on Behalf of the University of Arizona
- Applicants: Arizona Board of Regents On Behalf of the University of Arizona
- Inventors: Julie Ledford; Monica Kraft
- Web page: https://patentgrep.com/patent/US11110152B2

## CPC

- A61K 38/395: {Alveolar surfactant peptides; Pulmonary surfactant peptides}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61P 11/06: Antiasthmatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).

## Claims

### Claim 1

A method, comprising: delivering a composition comprising a peptide consisting of KEQCVEMYTD (SEQ ID NO: 4) to a lung cell in a subject, wherein said delivering results in one or more of enhancing SP-A activity in the cell, and treating asthma in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said composition reduces mucin production and/or reduces eosinophilia in said cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein said subject is obese.

### Claim 4 (depends on 1)

The method of claim 1, wherein said peptide binds to a receptor selected from the group consisting of Fc CD16/32, Sirp-alpha, toll-like receptor 2 (TLR-2) and epidermal growth factor receptor (EGFR).